BidaskClub upgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a strong-buy rating in a report released on Tuesday.
Several other research firms have also weighed in on DXCM. Barclays reiterated an equal weight rating and set a $60.00 price objective (down previously from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup cut shares of DexCom from an outperform rating to a market perform rating in a research report on Thursday, September 28th. Zacks Investment Research upgraded shares of DexCom from a sell rating to a hold rating in a research report on Monday, August 14th. Leerink Swann restated a buy rating and issued a $57.00 target price (down previously from $85.00) on shares of DexCom in a research report on Friday, September 29th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $78.00 target price (down previously from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $71.36.
DexCom (DXCM) traded down $0.28 on Tuesday, reaching $58.23. 1,435,100 shares of the company traded hands, compared to its average volume of 1,456,185. DexCom has a 52-week low of $42.62 and a 52-week high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.
Institutional investors have recently bought and sold shares of the company. Winslow Capital Management LLC bought a new position in shares of DexCom in the second quarter valued at approximately $117,451,000. State Street Corp lifted its stake in DexCom by 2.5% during the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after purchasing an additional 37,581 shares during the last quarter. Peregrine Capital Management LLC lifted its stake in DexCom by 24.5% during the third quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after purchasing an additional 77,868 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in DexCom by 111.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock valued at $693,000 after purchasing an additional 4,995 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its stake in DexCom by 67.2% during the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after purchasing an additional 97,479 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.com-unik.info/2017/12/15/dexcom-dxcm-raised-to-strong-buy-at-bidaskclub.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.